Aurisco Pharmaceutical Co Ltd (605116) - Total Liabilities

Latest as of June 2025: CN¥1.47 Billion CNY ≈ $215.58 Million USD

Based on the latest financial reports, Aurisco Pharmaceutical Co Ltd (605116) has total liabilities worth CN¥1.47 Billion CNY (≈ $215.58 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 605116 cash flow conversion to assess how effectively this company generates cash.

Aurisco Pharmaceutical Co Ltd - Total Liabilities Trend (2016–2024)

This chart illustrates how Aurisco Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Aurisco Pharmaceutical Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Aurisco Pharmaceutical Co Ltd Competitors by Total Liabilities

The table below lists competitors of Aurisco Pharmaceutical Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Xinjiang Xuefeng Sci-Tech SHG:603227	China	CN¥2.31 Billion
Cia Brasileira de Aluminio SA:CBAV3	Brazil	R$9.45 Billion
Shenzhen Terca Technology Co Ltd SHE:002213	China	CN¥137.20 Million
IMMUNOCORE HLDGS ADS/1 F:6YG	Germany	€686.24 Million
Hanwha Investment&Securities Co Ltd KO:003530	Korea	₩15.29 Trillion
Insigma SHG:600797	China	CN¥2.23 Billion
CTS Corporation NYSE:CTS	USA	$242.72 Million
Afry AB ST:AFRY	Sweden	Skr14.36 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Aurisco Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 605116 company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	4.51	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.61	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.38	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Aurisco Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Aurisco Pharmaceutical Co Ltd (2016–2024)

The table below shows the annual total liabilities of Aurisco Pharmaceutical Co Ltd from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	CN¥1.55 Billion ≈ $226.21 Million	+154.67%
2023-12-31	CN¥607.03 Million ≈ $88.83 Million	+74.09%
2022-12-31	CN¥348.68 Million ≈ $51.02 Million	+63.37%
2021-12-31	CN¥213.44 Million ≈ $31.23 Million	+44.23%
2020-12-31	CN¥147.98 Million ≈ $21.65 Million	+20.34%
2019-12-31	CN¥122.96 Million ≈ $17.99 Million	-7.65%
2018-12-31	CN¥133.16 Million ≈ $19.48 Million	+0.54%
2017-12-31	CN¥132.44 Million ≈ $19.38 Million	-31.03%
2016-12-31	CN¥192.01 Million ≈ $28.10 Million	--

About Aurisco Pharmaceutical Co Ltd

SHG:605116 China Biotechnology

Market Cap

$1.36 Billion

CN¥9.28 Billion CNY

Market Cap Rank

#7841 Global

#1958 in China

Share Price

CN¥22.85

Change (1 day)

+1.11%

52-Week Range

CN¥20.45 - CN¥34.43

All Time High

CN¥34.43